• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿比多尔,一种广谱抗病毒分子,对磷脂模型膜的膜转导作用。

Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes.

机构信息

Institute of Molecular and Cellular Biology, University Miguel Hernández, E-03206 Elche (Alicante), Spain.

出版信息

J Phys Chem B. 2010 Jul 1;114(25):8544-54. doi: 10.1021/jp102619w.

DOI:10.1021/jp102619w
PMID:20527735
Abstract

Arbidol, a broad and potent antiviral molecule, incorporates rapidly into membranes. To gain further insight into the mode of action of Arbidol, since the exact antiviral mechanism of Arbidol is unknown, I examined its interaction and effects on model membranes composed of saturated phospholipids by performing a detailed biophysical study using calorimetry and infrared spectroscopy. Arbidol interacts and modifies the physicochemical properties of the phospholipids in the membrane, having a significant effect on negatively charged phospholipids but a minor one on zwitterionic phospholipids. The data suggest that Arbidol is located at the interface of the membrane, participates in hydrogen bonding either with water or the phospholipid or both, and decreases the hydrogen bonding network of the phospholipids giving place to a phospholipid phase similar to the dehydrated solid one. The significant effects produced on negatively charged phospholipids suggest that the active molecule of Arbidol in the membrane is the protonated one, that is, the positively charged molecule. These data suggest that the potent antiviral effects of Arbidol are mediated at least in part through its membranotropic effects, likely giving place to the formation of perturbed membrane structures. These modifications interfere with proper membrane functioning and should be responsible for its broad antiviral activity.

摘要

阿比多尔是一种广谱强效的抗病毒分子,能迅速融入细胞膜。为了更深入地了解阿比多尔的作用机制,由于其确切的抗病毒机制尚不清楚,我通过使用量热法和红外光谱对由饱和磷脂组成的模型膜进行详细的生物物理研究,来检查阿比多尔与模型膜的相互作用及其对模型膜的影响。阿比多尔与膜中的磷脂相互作用并改变其理化性质,对带负电荷的磷脂有显著影响,但对带正电荷的磷脂影响较小。数据表明,阿比多尔位于膜的界面处,参与氢键的形成,与水或磷脂或两者都相互作用,并降低磷脂的氢键网络,形成类似于脱水固体的磷脂相。对带负电荷的磷脂产生的显著影响表明,阿比多尔在膜中的活性分子是质子化的,即带正电荷的分子。这些数据表明,阿比多尔的强效抗病毒作用至少部分是通过其跨膜作用介导的,可能导致膜结构的扰动形成。这些修饰干扰了膜的正常功能,应该是其广谱抗病毒活性的原因。

相似文献

1
Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes.阿比多尔,一种广谱抗病毒分子,对磷脂模型膜的膜转导作用。
J Phys Chem B. 2010 Jul 1;114(25):8544-54. doi: 10.1021/jp102619w.
2
The Location of the Protonated and Unprotonated Forms of Arbidol in the Membrane: A Molecular Dynamics Study.阿比朵尔质子化和非质子化形式在膜中的位置:一项分子动力学研究。
J Membr Biol. 2016 Jun;249(3):381-91. doi: 10.1007/s00232-016-9876-3. Epub 2016 Feb 3.
3
New Solid Forms of the Antiviral Drug Arbidol: Crystal Structures, Thermodynamic Stability, and Solubility.抗病毒药物阿比朵尔的新固体形式:晶体结构、热力学稳定性和溶解性
Mol Pharm. 2015 Nov 2;12(11):4154-65. doi: 10.1021/acs.molpharmaceut.5b00629. Epub 2015 Oct 19.
4
Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol.抗病毒药物阿比朵尔抑制流感病毒融合的结构基础。
Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):206-214. doi: 10.1073/pnas.1617020114. Epub 2016 Dec 21.
5
Design of inhibitors of influenza virus membrane fusion: synthesis, structure-activity relationship and in vitro antiviral activity of a novel indole series.设计流感病毒膜融合抑制剂:新型吲哚系列化合物的合成、构效关系及体外抗病毒活性。
Antiviral Res. 2013 Aug;99(2):125-35. doi: 10.1016/j.antiviral.2013.05.005. Epub 2013 May 22.
6
Differential scanning calorimetric study of the effect of the antimicrobial peptide gramicidin S on the thermotropic phase behavior of phosphatidylcholine, phosphatidylethanolamine and phosphatidylglycerol lipid bilayer membranes.抗菌肽短杆菌肽S对磷脂酰胆碱、磷脂酰乙醇胺和磷脂酰甘油脂质双分子层膜热致相行为影响的差示扫描量热研究
Biochim Biophys Acta. 1999 Mar 4;1417(2):211-23. doi: 10.1016/s0005-2736(99)00004-8.
7
Phospholipid/cholesterol model membranes: formation of cholesterol crystallites.磷脂/胆固醇模型膜:胆固醇微晶的形成。
Biochim Biophys Acta. 2003 Mar 10;1610(2):187-97. doi: 10.1016/s0005-2736(03)00017-8.
8
A study of carbobenzoxy-D-phenylalanine-L-phenylalanine-glycine, an inhibitor of membrane fusion, in phospholipid bilayers with multinuclear magnetic resonance.用多核磁共振研究膜融合抑制剂苄氧羰基-D-苯丙氨酸-L-苯丙氨酸-甘氨酸在磷脂双层中的情况。
Biochim Biophys Acta. 1995 May 4;1235(2):213-20. doi: 10.1016/0005-2736(95)80007-3.
9
Structure and orientation of the mammalian antibacterial peptide cecropin P1 within phospholipid membranes.哺乳动物抗菌肽天蚕素P1在磷脂膜中的结构与取向
J Mol Biol. 1996 May 24;258(5):860-70. doi: 10.1006/jmbi.1996.0293.
10
Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses.阿比多尔(盐酸阿比多尔):一种广谱抗病毒药物,可抑制具有医学重要性的节肢动物传播的黄病毒。
Viruses. 2018 Apr 10;10(4):184. doi: 10.3390/v10040184.

引用本文的文献

1
Harnessing immunity: Immunomodulatory therapies in COVID-19.利用免疫:COVID-19中的免疫调节疗法。
World J Virol. 2024 Jun 25;13(2):92521. doi: 10.5501/wjv.v13.i2.92521.
2
Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines.SARS-CoV-2 S2 亚基中可靶向的元件用于设计泛冠状病毒融合抑制剂和疫苗。
Signal Transduct Target Ther. 2023 May 10;8(1):197. doi: 10.1038/s41392-023-01472-x.
3
Frequently Used Allopathic and Traditional Medicine for COVID-19 Treatment and Feasibility of Their Integration.
常用于 COVID-19 治疗的对抗疗法和传统医学及其整合的可行性。
Chin J Integr Med. 2022 Nov;28(11):1040-1047. doi: 10.1007/s11655-021-3512-5. Epub 2022 May 4.
4
Drug-based therapeutic strategies for COVID-19-infected patients and their challenges.用于 COVID-19 感染患者的药物治疗策略及其面临的挑战。
Future Microbiol. 2021 Dec;16:1415-1451. doi: 10.2217/fmb-2021-0116. Epub 2021 Nov 23.
5
SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response.SARS-CoV-2:致病机制与宿主免疫应答。
Adv Exp Med Biol. 2021;1313:99-134. doi: 10.1007/978-3-030-67452-6_6.
6
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.乌米芬诺韦治疗住院的中重度新型冠状病毒肺炎患者:一项随机临床试验。
Int Immunopharmacol. 2021 Oct;99:107969. doi: 10.1016/j.intimp.2021.107969. Epub 2021 Jul 10.
7
Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.2019冠状病毒病中的疾病-药物及药物-药物相互作用:风险与评估
Biomed Pharmacother. 2021 Jul;139:111642. doi: 10.1016/j.biopha.2021.111642. Epub 2021 Apr 27.
8
Reducing SARS-CoV-2 pathological protein activity with small molecules.用小分子降低SARS-CoV-2病理性蛋白活性。
J Pharm Anal. 2021 Aug;11(4):383-397. doi: 10.1016/j.jpha.2021.03.012. Epub 2021 Apr 5.
9
Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives.对抗新型冠状病毒肺炎的新兴治疗方法:现状与未来展望
Front Mol Biosci. 2021 Mar 8;8:604447. doi: 10.3389/fmolb.2021.604447. eCollection 2021.
10
Combating COVID-19: The role of drug repurposing and medicinal plants.抗击 COVID-19:药物再利用和药用植物的作用。
J Infect Public Health. 2021 Apr;14(4):495-503. doi: 10.1016/j.jiph.2020.10.012. Epub 2020 Oct 27.